Join the Spain Delegation

With more exhibitors than ever Spain will maintain a 2,300 sq.ft. pavilion, comprised of companies, government institutions and research centers, showcasing their latest investment in biotechnology research and development (R&D).

Spain is a major player in biotechnology, as demonstrated through the following:

• Significant research centers and individual scientists with vast experience in both the national and international arena, creating a competitive atmosphere.
• A well developed institutional support structure, providing a business sector that can turn generous public and private investment in biotechnology into new products, therapies and services.
• A  favorable tax system for R&D investments – including tax relief of up to 40 percent  compared to other OECD countries.
• A social perception of biotechnology more positive than the European Union average

Biotech in Spain: Facts and Figures

• Good scientific basis: Spain ranked fourth in Europe in terms of biotechnology-related articles published in scientific journals.
• Average investment increase in R&D: 25%.
• New tools to support the growth of the emerging technological sector: Ingenio 2010 program with $2.65 billion.
• Over 500 companies with activities related to Biotechnology.

Save the date:

Click here for more information on Spain's seminar.

Biotechnology in Spain: High-Growth Industry
International Seminars Track
Monday, May 07, 2007
9:15 - 10:45 AM
Room Number: 253 C

The session will present an outlook for biotechnology in Spain, both from the scientific and business perspective.

• Detail growth indicators of biotechnology industry in Spain.
• Discuss the most active biozones in Spain.
• Present case studies: examples of business success.

Chair:

• Enrique Alejo, Trade Commissioner, Trade Commission of Spain

Speakers:

• Jose Luis Jorcano, General Director, GENOMA ESPAÑA
• Carlos Buesa, CEO, Oryzon Genomics
• Manel Balcells, President of the Executive Commission, Bioregio de Catalunya
• Federico Manrique, PRESIDENT, MADRID BIOREGION
• Eduardo Bravo, CEO, CELLERIX